. Author manuscript; available in PMC: 2017 Jul 25.

Published in final edited form as: Hemodial Int. 2017 Jun;21(Suppl 1):S110–S124. doi: 10.1111/hdi.12567

Table 2.

Summary of peer-reviewed clinical studies discussed in this review

Compound	Ref.	Pat	Durat weeks	Comp	Fe suppl	Hb	Ferritin	TIBC	TSAT	Hepcidin	Chol	VEGF
AKB-6548 Vadadustat	⁸⁶	NDD	20	Placebo	Oral Fe allowed	+	↓	↑	No change	↓	No effect	No change
	^88,89 (Meeting abstracts)	DD convers.	16	None, 3 dose cohorts	i.v. Fe permitted	+	n.r.^$	n.r.^$	n.r.^$	n.r.^$	n.r.^$	n.r.^$
GSK-1278863 Daprodustat	⁸¹	NDD	4	Placebo	Not specified	+	↓	↑^*	↓^*	↓	↓	No clear change^#
		DD	4	rhEPO	Not specified	+ 5 mg only	↓ (5 mg)	↑^*	No change (5 mg)	No change (5 mg)	↓	No clear change^#
FG-4592 Roxadustat	⁸³	NDD	4	Placebo	i.v. Fe prohibited, oral Fe allowed	+ Dose-dep.	↓^& Also placebo	↑	↓	↓	n.r.	n.r.
	⁸⁵	DD Incident patients	12	None	One i.v., 2 oral and one no-iron cohort	+ Iron-indep.	↓	↑	↓	↓	n.r	n.r
	⁸⁴	NDD	16–24	None, 6-cohort dose-finding study	i.v. Fe prohibited, oral Fe allowed	+ Starting dose-dep.	↓, for BL Ferritin ≥100 ng/mL	n.r.	↓ Initially	↓	↓	n.r.
	⁸²	DD convers.	6 or 19	rhEPO	Oral Fe allowed, i.v. Fe as rescue	+	No change	↑ At 6 wks	No change	↓ At 19 wks	↓	n.r.

+ denotes effectiveness in changing or maintaining hemoglobin (Hb);

denotes trends, small, or statistically nonsignificant changes;

denotes that high interpatient variability was observed;

not statistically significant compared to placebo;

not reported in the meeting abstracts, manuscript containing iron data in preparation;

BL, base line; convers., conversion from ESA therapy to HIF-PHI; Comp, Comparator; n.r., not reported; Pat, either dialysis-dependent (DD) or nondialysis-dependent (NDD) CKD patients, incident patients are newly initiated EPO-naïve hemodialysis or peritoneal dialysis patients.